Quantcast

LOUISIANA RECORD

Friday, April 19, 2024

Suit filed against Xarelto makers

Medical malpractice 05

NEW ORLEANS – A Virginia representative has filed suit against the makers of Xarelto alleging it caused an irreversible bleed.

James Jarrett, on behalf of Ruth Frances Jarrett, deceased, filed a complaint on April 11 in the U.S. District Court for the Eastern District of Louisiana against Jansen Research & Development LLC, Jansen Ortho LLC, Jansen Pharmaceuticals Inc., et al., alleging that they violated the Consumer Protection Law.

According to the complaint, the plaintiff alleges that Ruth Frances Jarrett, deceased, first began using Xarelto on April 21, 2014, and used it up to Sept. 6, 2014. As a result of using Xarelto, she suffered serious and dangerous side effects including life-threatening bleeding, severe and personal injuries, physical pain and mental anguish, shortened life expectancy, loss of earnings and hospitalization and medical treatment expenses.

The plaintiff holds the defendants responsible because the defendants allegedly designed, researched, manufactured, tested, advertised, promoted, marketed, distributed and sold Xarelto. They allegedly also failed to properly investigate, research, study and define fully and adequately the safety profile of Xarelto; failed to adequately test Xarelto; failed to provide adequate warnings; failed to disclose the need for dose adjustments; failed to provide adequate instructions; and failed to warn the medical professionals that there is no effective agent to reverse the effects of Xarelto.

The plaintiff requests a trial by jury and seeks compensation for all damages in an amount to be determined at trial, punitive damages, prejudgment and post-judgment interest, attorneys' fees, litigation costs and expenses and such other relief as the court may deem just and proper. He is represented by Ethan L. Shaw, John P. Cowart and Matthew J. Riley of Shaw Cowart LLP in Austin, Texas.

U.S. District Court for the Eastern District of Louisiana Case number 2:16-cv-02934

More News